免疫治疗后完全缓解的胎盘部位滋养细胞肿瘤患者足月妊娠
本文报告一例23岁I期胎盘部位滋养细胞肿瘤患者拒绝子宫切除,肿瘤PD-L1染色提示免疫反应性,接受帕博利珠单抗200 mg每2周静脉治疗后β-hCG降至不可测,随后自然受孕并足月阴道分娩,产后6周无病生存。结论提示免疫治疗可消除早期PD-L1阳性胎盘部位滋养细胞肿瘤并保留生育功能。
要点
- PD-L1阳性早期胎盘部位滋养细胞肿瘤可尝试免疫治疗保留生育
- 帕博利珠单抗200 mg每2周后β-hCG降至不可测
- 免疫治疗后可达足月妊娠及阴道分娩
核心结论
- 免疫治疗可消除早期PD-L1阳性胎盘部位滋养细胞肿瘤,随后可正常妊娠。
研究设计与样本
- 个案报告:一例23岁I期胎盘部位滋养细胞肿瘤患者拒绝子宫切除。
主要发现
- 肿瘤PD-L1染色提示免疫反应性。
- 帕博利珠单抗200 mg每2周静脉治疗,第3周期时β-hCG降至不可测。
- 患者随后受孕并足月阴道分娩(剖宫产后阴道分娩),产后6周无病证据。
临床怎么用
- 对希望保留生育的早期PD-L1阳性胎盘部位滋养细胞肿瘤患者,免疫治疗可作为替代子宫切除的选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Standard treatment for placental site trophoblastic tumor is hysterectomy. This may be unacceptable to women desiring fertility. Cells aberrant in placental site trophoblastic tumor display an ability to invade normal tissue while evading the immune system. CASE: We present a case of a 23-year-old woman with stage I placental site trophoblastic tumor who declined hysterectomy. Tumor assay for program cell death-ligand 1 staining was performed and suggestive of an immune-responsive tumor. The patient initiated intravenous pembrolizumab 200 mg every 2 weeks, and by cycle 3 her β-hCG level fell to undetectable. She subsequently conceived and went on to have an uncomplicated term vaginal birth after cesarean. At 6 weeks postpartum, she remained without evidence of disease. CONCLUSION: Immunotherapy can eliminate early program cell death-ligand 1-positive placental site trophoblastic tumor with subsequent normal pregnancy.
引用
- Polnaszek B, Mullen M, Bligard K, et al. Term Pregnancy After Complete Response of Placental Site Trophoblastic Tumor to Immunotherapy. Obstet Gynecol. 2021. PMID: 34259474. doi:10.1097/AOG.0000000000004434
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。